Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.67 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.52 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678524 | 1.00 | IRAK4 (0.67) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21705185 | 0.83 | IRAK4 (0.48) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23425374 | 0.83 | IRAK4 (0.48) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21678751 | 0.83 | IRAK4 (0.48) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL26528461 | 0.82 | IRAK4 (0.75) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23425377 | 0.82 | IRAK4 (0.47) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23425376 | 0.82 | IRAK4 (0.47) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL16765219 | 0.82 | JAK3 (0.54) | IRAK4JAK3 | |
| Bromide SCHEMBL16764564 | 0.81 | JAK3 (0.53) | IRAK4JAK3 | |
| SCHEMBL21678424 | 0.81 | IRAK4 (0.63) | IRAK4IRAK2CLK1CLK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020033955-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |